董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark Iwicki | 男 | Chairperson and Director | 54 | 未披露 | 未持股 | 2021-06-22 |
| Timothy P. Noyes | 男 | Chief Executive Officer and Director | 59 | 未披露 | 未持股 | 2021-06-22 |
| Joshua Resnick | 男 | Director | 46 | 未披露 | 未持股 | 2021-06-22 |
| David Grayzel | 男 | Director | 53 | 未披露 | 未持股 | 2021-06-22 |
| Maha Katabi | 女 | Director | 48 | 未披露 | 未持股 | 2021-06-22 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Timothy P. Noyes | 男 | Chief Executive Officer and Director | 59 | 未披露 | 未持股 | 2021-06-22 |
| George A. Eldridge | 男 | Chief Financial Officer and Treasurer | 58 | 未披露 | 未持股 | 2021-06-22 |
| Benjamin T. Dake | 男 | President, Chief Operating Officer and Secretary | 45 | 50.21万美元 | 未持股 | 2021-06-22 |
| Hunter Gillies | 男 | Chief Medical Officer | 55 | 42.34万美元 | 未持股 | 2021-06-22 |
| Ralph Niven | 男 | Chief Development Officer | 61 | 43.32万美元 | 未持股 | 2021-06-22 |
董事简历
中英对照 | 中文 | 英文- Mark Iwicki
-
Mark Iwicki自2020年5月起担任Third Harmonic Bio，Inc.董事会主席。Iwicki先生还自2015年3月起担任Kala制药有限公司的首席执行官兼执行Shlomo Kramer。在加入Kala制药之前，Iwicki先生于2014年1月至2014年11月担任Civitas Therapeutics，Inc.的总裁兼首席执行官。在加入Civitas之前，Iwicki先生于2012年12月至2014年1月担任Tarveda Therapeutics，Inc.（前身为Blend Therapeutics，Inc.）的总裁兼首席执行官。在加入Blend之前，Iwicki先生于2007年10月至2012年6月担任Sunovion Pharmaceuticals Inc.（前身为Sepracor Inc.）的总裁兼首席执行官。在加入Sunovion之前，Iwicki先生于1998年3月至2007年10月担任诺华制药公司的副总裁兼业务部门负责人。在此之前，Iwicki先生曾在Astra Merck Inc.和默克制药公司担任销售职位。除了在Third Harmonic Bio，Inc.董事会任职外，Iwicki先生目前还在Merus N.V。 、Pulmatrix公司、Akero Therapeutics, Inc.、Aerovate Therapeutics, Inc.、和Kala制药有限公司在过去五年中，Iwicki先生还曾在Aimmune Therapeutics,Inc.董事会任职。Iwicki先生拥有Ball State University市场营销学学士和Loyola University Maryland工商管理硕士学位。
Mark Iwicki,has served as Kala Pharmaceuticals, Inc. Chief Executive Officer and Chairman of Kala Pharmaceuticals, Inc. board of directors since September 2015. Mr. Iwicki previously served as Kala Pharmaceuticals, Inc. President from August 2017 to December 2021 and as Executive Chairman of Kala Pharmaceuticals, Inc. board of directors from April 2015 to September 2015. Prior to joining Kala Pharmaceuticals, Inc. , Mr. Iwicki served as President and Chief Executive Officer of Civitas Therapeutics, Inc., or Civitas, a biopharmaceutical company, from January 2014 to November 2014. Prior to Civitas, Mr. Iwicki served as President and Chief Executive Officer at Blend Therapeutics, Inc., or Blend, a biopharmaceutical company, from December 2012 to January 2014. Prior to Blend, Mr. Iwicki was President and Chief Executive Officer of Sunovion, a pharmaceutical company. Mr. Iwicki was at Sepracor Inc./Sunovion from October 2007 to June 2012. Prior to joining Sepracor Inc., Mr. Iwicki was Vice President and Business Unit Head at Novartis Pharmaceuticals Corporation, a biopharmaceutical company. He was at Novartis from March 1998 to October 2007. Prior to that, Mr. Iwicki held management positions at Astra Merck Inc. and Merck & Co., Inc. In addition to serving on Kala Pharmaceuticals, Inc. board of directors, Mr. Iwicki also currently serves on the boards of Aerovate Therapeutics, Inc., Merus N.V., Akero Therapeutics, Inc. and Third Harmonic Bio, Inc. and formerly served on the board of Aimmune Therapeutics, Inc. and Pulmatrix Inc., all publicly-traded companies. Mr. Iwicki holds a B.S. in Business Administration from Ball State University and an M.B.A. from Loyola University. - Mark Iwicki自2020年5月起担任Third Harmonic Bio，Inc.董事会主席。Iwicki先生还自2015年3月起担任Kala制药有限公司的首席执行官兼执行Shlomo Kramer。在加入Kala制药之前，Iwicki先生于2014年1月至2014年11月担任Civitas Therapeutics，Inc.的总裁兼首席执行官。在加入Civitas之前，Iwicki先生于2012年12月至2014年1月担任Tarveda Therapeutics，Inc.（前身为Blend Therapeutics，Inc.）的总裁兼首席执行官。在加入Blend之前，Iwicki先生于2007年10月至2012年6月担任Sunovion Pharmaceuticals Inc.（前身为Sepracor Inc.）的总裁兼首席执行官。在加入Sunovion之前，Iwicki先生于1998年3月至2007年10月担任诺华制药公司的副总裁兼业务部门负责人。在此之前，Iwicki先生曾在Astra Merck Inc.和默克制药公司担任销售职位。除了在Third Harmonic Bio，Inc.董事会任职外，Iwicki先生目前还在Merus N.V。 、Pulmatrix公司、Akero Therapeutics, Inc.、Aerovate Therapeutics, Inc.、和Kala制药有限公司在过去五年中，Iwicki先生还曾在Aimmune Therapeutics,Inc.董事会任职。Iwicki先生拥有Ball State University市场营销学学士和Loyola University Maryland工商管理硕士学位。
- Mark Iwicki,has served as Kala Pharmaceuticals, Inc. Chief Executive Officer and Chairman of Kala Pharmaceuticals, Inc. board of directors since September 2015. Mr. Iwicki previously served as Kala Pharmaceuticals, Inc. President from August 2017 to December 2021 and as Executive Chairman of Kala Pharmaceuticals, Inc. board of directors from April 2015 to September 2015. Prior to joining Kala Pharmaceuticals, Inc. , Mr. Iwicki served as President and Chief Executive Officer of Civitas Therapeutics, Inc., or Civitas, a biopharmaceutical company, from January 2014 to November 2014. Prior to Civitas, Mr. Iwicki served as President and Chief Executive Officer at Blend Therapeutics, Inc., or Blend, a biopharmaceutical company, from December 2012 to January 2014. Prior to Blend, Mr. Iwicki was President and Chief Executive Officer of Sunovion, a pharmaceutical company. Mr. Iwicki was at Sepracor Inc./Sunovion from October 2007 to June 2012. Prior to joining Sepracor Inc., Mr. Iwicki was Vice President and Business Unit Head at Novartis Pharmaceuticals Corporation, a biopharmaceutical company. He was at Novartis from March 1998 to October 2007. Prior to that, Mr. Iwicki held management positions at Astra Merck Inc. and Merck & Co., Inc. In addition to serving on Kala Pharmaceuticals, Inc. board of directors, Mr. Iwicki also currently serves on the boards of Aerovate Therapeutics, Inc., Merus N.V., Akero Therapeutics, Inc. and Third Harmonic Bio, Inc. and formerly served on the board of Aimmune Therapeutics, Inc. and Pulmatrix Inc., all publicly-traded companies. Mr. Iwicki holds a B.S. in Business Administration from Ball State University and an M.B.A. from Loyola University.
- Timothy P. Noyes
-
Timothy P. Noyes于2006年4月加入Proteon，担任我司总裁兼首席执行官，还从加入Proteon开始一直担任我司董事。从2002年到2006年，Noyes先生担任Trine Pharmaceuticals, Inc.的首席运营官。加入Trine以前，从1996年到2001年，Noyes先生担任过吉尔泰克斯制药公司（GelTex Pharmaceuticals）的几个管理职位，之后该公司被美国健赞公司（Genzyme Corporation）收购。收购以后，从2001年到2002年，他担任过吉尔泰克斯制药公司的总裁与肾脏部门的总裁。加入吉尔泰克斯制药公司前，他在美国默克公司（Merck & Co.）的高血压和心力衰竭事业部和管理式照护部门的多个职位任职几年，并研究其依那普利和奥美拉唑产品。Noyes先生在哈佛学院（Harvard College）获得文学学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
Timothy P. Noyes has served as our Chief Executive Officer since February 2021 and a member of our board of directors since April 2021. Prior to joining the Company, from October 2019 to February 2021 Mr. Noyes served as President and Chief Executive Officer and a member of the board of directors of Arcuate Therapeutics, Inc. From April 2006 to September 2019 Mr. Noyes served as a member of the board of directors of ArTara Therapeutics, Inc., publicly traded pharmaceutical company formerly known as Proteon Therapeutics, Inc., or Proteon. From April 2006 to January 2020 Mr. Noyes also served as President and Chief Executive Officer of Proteon, until Proteon completed its merger with ArTara Therapeutics Inc. From January 2002 to March 2006 Mr. Noyes served as Chief Operating Officer of Trine Pharmaceuticals, Inc., or Trine. Before joining Trine, Mr. Noyes held several management positions with GelTex Pharmaceuticals Inc. from 1996 to 2001 prior to its acquisition by Genzyme Corporation. After the acquisition, from 2001 to 2002 he held the positions of President, Renal Division and President, GelTex Pharmaceuticals. Prior to GelTex, he worked for several years at Merck & Co. across multiple roles in its hypertension and heart failure group and managed care division, and on its Vasotec and Prilosec products. Mr. Noyes received an A.B. from Harvard College and an M.B.A. from Harvard Business School. - Timothy P. Noyes于2006年4月加入Proteon，担任我司总裁兼首席执行官，还从加入Proteon开始一直担任我司董事。从2002年到2006年，Noyes先生担任Trine Pharmaceuticals, Inc.的首席运营官。加入Trine以前，从1996年到2001年，Noyes先生担任过吉尔泰克斯制药公司（GelTex Pharmaceuticals）的几个管理职位，之后该公司被美国健赞公司（Genzyme Corporation）收购。收购以后，从2001年到2002年，他担任过吉尔泰克斯制药公司的总裁与肾脏部门的总裁。加入吉尔泰克斯制药公司前，他在美国默克公司（Merck & Co.）的高血压和心力衰竭事业部和管理式照护部门的多个职位任职几年，并研究其依那普利和奥美拉唑产品。Noyes先生在哈佛学院（Harvard College）获得文学学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
- Timothy P. Noyes has served as our Chief Executive Officer since February 2021 and a member of our board of directors since April 2021. Prior to joining the Company, from October 2019 to February 2021 Mr. Noyes served as President and Chief Executive Officer and a member of the board of directors of Arcuate Therapeutics, Inc. From April 2006 to September 2019 Mr. Noyes served as a member of the board of directors of ArTara Therapeutics, Inc., publicly traded pharmaceutical company formerly known as Proteon Therapeutics, Inc., or Proteon. From April 2006 to January 2020 Mr. Noyes also served as President and Chief Executive Officer of Proteon, until Proteon completed its merger with ArTara Therapeutics Inc. From January 2002 to March 2006 Mr. Noyes served as Chief Operating Officer of Trine Pharmaceuticals, Inc., or Trine. Before joining Trine, Mr. Noyes held several management positions with GelTex Pharmaceuticals Inc. from 1996 to 2001 prior to its acquisition by Genzyme Corporation. After the acquisition, from 2001 to 2002 he held the positions of President, Renal Division and President, GelTex Pharmaceuticals. Prior to GelTex, he worked for several years at Merck & Co. across multiple roles in its hypertension and heart failure group and managed care division, and on its Vasotec and Prilosec products. Mr. Noyes received an A.B. from Harvard College and an M.B.A. from Harvard Business School.
- Joshua Resnick
-
Joshua Resnick自2019年2月以来一直担任我们的董事会成员。Resnick博士目前担任RA Capital Management的董事总经理，自2018年10月起担任该职位。Resnick博士此前曾于2016年1月至2018年9月担任SV Health Investors的合伙人，并于2014年至2016年1月担任MRL Ventures Fund的总裁兼管理合伙人，该基金是他在默克公司（Merck&Co.）内部建立和管理的专注于治疗的早期企业风险基金。Resnick博士在马萨诸塞州总医院（Massachusetts General Hospital）急诊医学部工作。Resnick博士分别于2016年11月至2018年9月和2016年7月至2018年9月担任KalVistaPharmaceuticals，Inc.和AVROBIO，Inc.的董事会成员。Resnick博士在威廉姆斯学院（Williams College）获得化学学士学位，在宾夕法尼亚大学医学院（University of Pennsylvania School of Medicine）获得医学博士学位，在沃顿商学院（Wharton School of Business）获得工商管理硕士学位。
Joshua Resnick,has served as a member of Sionna Therapeutics, Inc. board of directors since December 2019. Dr. Resnick is a senior managing director at RA Capital Management, L.P., where he previously served as a Managing Director from October 2018 to March 2023. Dr. Resnick is also a faculty member at Harvard Medical School and continues to practice medicine as an attending physician in the Department of Emergency Medicine at Massachusetts General Hospital. Dr. Resnick has served on the boards of directors of PepGen Inc. (NASDAQ: PEPG) since November 2020, Aerovate Therapeutics, Inc. (NASDAQ: AVTE) since August 2020, as well as from October 2018 to February 2020, and Vor Biopharma Inc. (NASDAQ: VOR) since February 2019. Dr. Resnick received a B.A. in chemistry from Williams College, an M.D. from the University of Pennsylvania Perelman School of Medicine and an M.B.A. from The Wharton School of the University of Pennsylvania. - Joshua Resnick自2019年2月以来一直担任我们的董事会成员。Resnick博士目前担任RA Capital Management的董事总经理，自2018年10月起担任该职位。Resnick博士此前曾于2016年1月至2018年9月担任SV Health Investors的合伙人，并于2014年至2016年1月担任MRL Ventures Fund的总裁兼管理合伙人，该基金是他在默克公司（Merck&Co.）内部建立和管理的专注于治疗的早期企业风险基金。Resnick博士在马萨诸塞州总医院（Massachusetts General Hospital）急诊医学部工作。Resnick博士分别于2016年11月至2018年9月和2016年7月至2018年9月担任KalVistaPharmaceuticals，Inc.和AVROBIO，Inc.的董事会成员。Resnick博士在威廉姆斯学院（Williams College）获得化学学士学位，在宾夕法尼亚大学医学院（University of Pennsylvania School of Medicine）获得医学博士学位，在沃顿商学院（Wharton School of Business）获得工商管理硕士学位。
- Joshua Resnick,has served as a member of Sionna Therapeutics, Inc. board of directors since December 2019. Dr. Resnick is a senior managing director at RA Capital Management, L.P., where he previously served as a Managing Director from October 2018 to March 2023. Dr. Resnick is also a faculty member at Harvard Medical School and continues to practice medicine as an attending physician in the Department of Emergency Medicine at Massachusetts General Hospital. Dr. Resnick has served on the boards of directors of PepGen Inc. (NASDAQ: PEPG) since November 2020, Aerovate Therapeutics, Inc. (NASDAQ: AVTE) since August 2020, as well as from October 2018 to February 2020, and Vor Biopharma Inc. (NASDAQ: VOR) since February 2019. Dr. Resnick received a B.A. in chemistry from Williams College, an M.D. from the University of Pennsylvania Perelman School of Medicine and an M.B.A. from The Wharton School of the University of Pennsylvania.
- David Grayzel
-
David Grayzel自2020年8月以来一直担任我们的董事会成员。Grayzel博士于2010年6月加入Atlas Venture Inc.，自2014年4月起担任合伙人。在此之前，Grayzel博士从2011年6月开始联合创立Arteaus Therapeutics，LLC，并担任其首席执行官，直到2014年1月该公司被礼来公司收购，担任Annovation Biopharma的联合创始人兼首席执行官，Inc.从2011年5月到2015年2月被The Medicines Company收购，担任Delinia的创始董事会成员，Inc.从2015年9月到2017年1月被新基医药公司收购，担任Cadent Therapeutics，Inc.的联合创始人和董事会成员，直到2020年12月被Novartis收购。Grayzel博士目前是上市生物技术公司Surface Oncology的联合创始人兼董事会成员，并于2014年4月至2015年5月担任首席执行官，并于2014年4月至2017年1月担任董事会主席，是Q32Bio的联合创始人兼董事会成员。他还担任Xilio Therapeutics和Affinia Therapeutics的董事会成员，以及Day One Biopharmaceuticals的董事会观察员。Grayzel博士是Acera School，Inc.的董事会成员。马萨诸塞州科学，创新和领导学院。他还担任多个组织的顾问，包括纪念斯隆·凯特琳癌症中心（MSKCC）技术发展基金，美国心脏协会（American Heart Association）的勇敢想法，以及包括洛克菲勒大学（Rockefeller University），MSKCC和康奈尔大学在内的TDI科学顾问委员会成员。Grayzel博士获得了斯坦福大学心理学学士学位，哈佛医学院医学博士学位，并在马萨诸塞州总医院完成了内科实习和住院医师培训。
David Grayzel has served as a member of our board of directors since August 2020. Dr. Grayzel joined Atlas Venture Inc. in June 2010 and has been a Partner since April 2014. Before that, Dr. Grayzel co-founded and served as Chief Executive Officer of Arteaus Therapeutics, LLC from June 2011 until it was acquired by Eli Lilly and Company in January 2014 served as co-founder and Chief Executive Officer of Annovation Biopharma, Inc. from May 2011 until it was acquired by The Medicines Company in February 2015 served as a founding board member of Delinia, Inc. from September 2015 until it was acquired by Celgene Corporation in January 2017 and served as a co-founder and a member of the board of directors of Cadent Therapeutics, Inc., until it was acquired by Novartis in December 2020. Dr. Grayzel is currently a co-founder and board member of Surface Oncology, a publicly traded biotechnology company, and served as its Chief Executive Officer from April 2014 to May 2015 and as Chairman of its board of directors from April 2014 to January 2017 and is a co-founder and board member of Q32 Bio. He also serves as a board member of Xilio Therapeutics and Affinia Therapeutics, and as a board observer at Day One Biopharmaceuticals. Dr. Grayzel serves on the board of directors of Acera School, Inc. The Massachusetts School for Science, Creativity, and Leadership. He also serves as an advisor to several organizations including Memorial Sloan Kettering Cancer Center’s (MSKCC) Technology Development Fund, the American Heart Association’s One Brave Idea, and is on the Scientific Advisory Board of the Tri-TDI that includes Rockefeller University, MSKCC, and Cornell University. Dr. Grayzel received a B.A. in Psychology from Stanford University, an M.D. from Harvard Medical School, and completed his internship and residency training in Internal Medicine at Massachusetts General Hospital. - David Grayzel自2020年8月以来一直担任我们的董事会成员。Grayzel博士于2010年6月加入Atlas Venture Inc.，自2014年4月起担任合伙人。在此之前，Grayzel博士从2011年6月开始联合创立Arteaus Therapeutics，LLC，并担任其首席执行官，直到2014年1月该公司被礼来公司收购，担任Annovation Biopharma的联合创始人兼首席执行官，Inc.从2011年5月到2015年2月被The Medicines Company收购，担任Delinia的创始董事会成员，Inc.从2015年9月到2017年1月被新基医药公司收购，担任Cadent Therapeutics，Inc.的联合创始人和董事会成员，直到2020年12月被Novartis收购。Grayzel博士目前是上市生物技术公司Surface Oncology的联合创始人兼董事会成员，并于2014年4月至2015年5月担任首席执行官，并于2014年4月至2017年1月担任董事会主席，是Q32Bio的联合创始人兼董事会成员。他还担任Xilio Therapeutics和Affinia Therapeutics的董事会成员，以及Day One Biopharmaceuticals的董事会观察员。Grayzel博士是Acera School，Inc.的董事会成员。马萨诸塞州科学，创新和领导学院。他还担任多个组织的顾问，包括纪念斯隆·凯特琳癌症中心（MSKCC）技术发展基金，美国心脏协会（American Heart Association）的勇敢想法，以及包括洛克菲勒大学（Rockefeller University），MSKCC和康奈尔大学在内的TDI科学顾问委员会成员。Grayzel博士获得了斯坦福大学心理学学士学位，哈佛医学院医学博士学位，并在马萨诸塞州总医院完成了内科实习和住院医师培训。
- David Grayzel has served as a member of our board of directors since August 2020. Dr. Grayzel joined Atlas Venture Inc. in June 2010 and has been a Partner since April 2014. Before that, Dr. Grayzel co-founded and served as Chief Executive Officer of Arteaus Therapeutics, LLC from June 2011 until it was acquired by Eli Lilly and Company in January 2014 served as co-founder and Chief Executive Officer of Annovation Biopharma, Inc. from May 2011 until it was acquired by The Medicines Company in February 2015 served as a founding board member of Delinia, Inc. from September 2015 until it was acquired by Celgene Corporation in January 2017 and served as a co-founder and a member of the board of directors of Cadent Therapeutics, Inc., until it was acquired by Novartis in December 2020. Dr. Grayzel is currently a co-founder and board member of Surface Oncology, a publicly traded biotechnology company, and served as its Chief Executive Officer from April 2014 to May 2015 and as Chairman of its board of directors from April 2014 to January 2017 and is a co-founder and board member of Q32 Bio. He also serves as a board member of Xilio Therapeutics and Affinia Therapeutics, and as a board observer at Day One Biopharmaceuticals. Dr. Grayzel serves on the board of directors of Acera School, Inc. The Massachusetts School for Science, Creativity, and Leadership. He also serves as an advisor to several organizations including Memorial Sloan Kettering Cancer Center’s (MSKCC) Technology Development Fund, the American Heart Association’s One Brave Idea, and is on the Scientific Advisory Board of the Tri-TDI that includes Rockefeller University, MSKCC, and Cornell University. Dr. Grayzel received a B.A. in Psychology from Stanford University, an M.D. from Harvard Medical School, and completed his internship and residency training in Internal Medicine at Massachusetts General Hospital.
- Maha Katabi
-
Maha Katabi，自2022年8月起担任Rayzebio，Inc.董事会成员。Katabi博士于2019年4月作为合伙人加入生物技术投资公司Sofinnova Investments，自2020年3月起担任普通合伙人。此前，卡塔比博士曾于2018年8月至2019年4月担任风险投资公司Oxalis Capital的创始管理合伙人。从2008年9月到2018年1月，卡塔比博士在Sectoral Asset Management担任投资经理，后来成为私人股本合伙人。Sectoral Asset Management是一家专注于全球医疗保健领域的投资顾问，她是投资于小型和私人生物技术公司的一系列基金的投资组合经理。在加入Sectoral之前，Katabi博士从2004年到2008年在Ventures West担任副总裁，在那里她专注于生命科学行业的早期风险投资。1999年，她在专注于大学初创企业的种子基金T2C2 Capital Bio开始了她的风险投资生涯。卡塔比博士从2021年3月起担任Gyroscope Therapeutics的董事会成员，直到2022年2月被诺华收购；从2020年5月起担任Amplyx Pharmaceuticals的董事会成员，直到2021年4月被辉瑞收购。Katabi博士目前是Aerovate Therapeutics, Inc.、Quanta Therapeutics公司、Sofinnova Investments公司和Vera Therapeutics公司的董事会成员。Aerovate Therapeutics公司是一家上市的临床阶段生物制药公司。她是Exactis Innovation的董事会主席，Exactis Innovation是一家非营利的泛加拿大精准肿瘤研究网络，也是Yale Ventures旗下AmplifyHERscience的顾问。Katabi博士在麦吉尔大学获得药理学博士学位和生物学学士学位，并于2011年获得CFA证书。
Maha Katabi,has served as a member of Rayzebio, Inc. board of directors since August 2022. Dr. Katabi joined Sofinnova Investments, a biotechnology investment firm, in April 2019 as a partner and has been a general partner since March 2020. Previously, Dr. Katabi served as a founding managing partner at Oxalis Capital, a venture capital firm, from August 2018 until April 2019. From September 2008 until January 2018, Dr. Katabi served as an investment manager and later partner, private equity at Sectoral Asset Management, an investment advisor exclusively focused on the global healthcare sector, where she was the portfolio manager of a family of funds investing in small cap and private biotech companies. Prior to joining Sectoral, Dr. Katabi served as a vice president at Ventures West from 2004 until 2008, where she focused on early-stage venture investments in the life sciences industry. She started her venture capital career in 1999 with T2C2 Capital Bio, a seed fund focused on university start-ups. Dr. Katabi served as a member of the board of directors of Gyroscope Therapeutics from March 2021 until it was acquired by Novartis in February 2022, and a member of the board of directors of Amplyx Pharmaceuticals from May 2020 until it was acquired by Pfizer in April 2021. Dr. Katabi is currently a board member of Aerovate Therapeutics, Inc., a publicly traded clinical-stage biopharmaceutical company, Quanta Therapeutics, Inc., Sofinnova Investments, Inc., and Vera Therapeutics Inc., a publicly traded clinical-stage biotechnology company. She serves as chairman of the board of directors of Exactis Innovation, a not-for-profit pan-Canadian research network for precision oncology, and an advisor to amplifyHERscience, within Yale Ventures. Dr. Katabi received a Ph.D. in Pharmacology and a B.S. in Biology at McGill University and her CFA charter in 2011. - Maha Katabi，自2022年8月起担任Rayzebio，Inc.董事会成员。Katabi博士于2019年4月作为合伙人加入生物技术投资公司Sofinnova Investments，自2020年3月起担任普通合伙人。此前，卡塔比博士曾于2018年8月至2019年4月担任风险投资公司Oxalis Capital的创始管理合伙人。从2008年9月到2018年1月，卡塔比博士在Sectoral Asset Management担任投资经理，后来成为私人股本合伙人。Sectoral Asset Management是一家专注于全球医疗保健领域的投资顾问，她是投资于小型和私人生物技术公司的一系列基金的投资组合经理。在加入Sectoral之前，Katabi博士从2004年到2008年在Ventures West担任副总裁，在那里她专注于生命科学行业的早期风险投资。1999年，她在专注于大学初创企业的种子基金T2C2 Capital Bio开始了她的风险投资生涯。卡塔比博士从2021年3月起担任Gyroscope Therapeutics的董事会成员，直到2022年2月被诺华收购；从2020年5月起担任Amplyx Pharmaceuticals的董事会成员，直到2021年4月被辉瑞收购。Katabi博士目前是Aerovate Therapeutics, Inc.、Quanta Therapeutics公司、Sofinnova Investments公司和Vera Therapeutics公司的董事会成员。Aerovate Therapeutics公司是一家上市的临床阶段生物制药公司。她是Exactis Innovation的董事会主席，Exactis Innovation是一家非营利的泛加拿大精准肿瘤研究网络，也是Yale Ventures旗下AmplifyHERscience的顾问。Katabi博士在麦吉尔大学获得药理学博士学位和生物学学士学位，并于2011年获得CFA证书。
- Maha Katabi,has served as a member of Rayzebio, Inc. board of directors since August 2022. Dr. Katabi joined Sofinnova Investments, a biotechnology investment firm, in April 2019 as a partner and has been a general partner since March 2020. Previously, Dr. Katabi served as a founding managing partner at Oxalis Capital, a venture capital firm, from August 2018 until April 2019. From September 2008 until January 2018, Dr. Katabi served as an investment manager and later partner, private equity at Sectoral Asset Management, an investment advisor exclusively focused on the global healthcare sector, where she was the portfolio manager of a family of funds investing in small cap and private biotech companies. Prior to joining Sectoral, Dr. Katabi served as a vice president at Ventures West from 2004 until 2008, where she focused on early-stage venture investments in the life sciences industry. She started her venture capital career in 1999 with T2C2 Capital Bio, a seed fund focused on university start-ups. Dr. Katabi served as a member of the board of directors of Gyroscope Therapeutics from March 2021 until it was acquired by Novartis in February 2022, and a member of the board of directors of Amplyx Pharmaceuticals from May 2020 until it was acquired by Pfizer in April 2021. Dr. Katabi is currently a board member of Aerovate Therapeutics, Inc., a publicly traded clinical-stage biopharmaceutical company, Quanta Therapeutics, Inc., Sofinnova Investments, Inc., and Vera Therapeutics Inc., a publicly traded clinical-stage biotechnology company. She serves as chairman of the board of directors of Exactis Innovation, a not-for-profit pan-Canadian research network for precision oncology, and an advisor to amplifyHERscience, within Yale Ventures. Dr. Katabi received a Ph.D. in Pharmacology and a B.S. in Biology at McGill University and her CFA charter in 2011.
高管简历
中英对照 | 中文 | 英文- Timothy P. Noyes
Timothy P. Noyes于2006年4月加入Proteon，担任我司总裁兼首席执行官，还从加入Proteon开始一直担任我司董事。从2002年到2006年，Noyes先生担任Trine Pharmaceuticals, Inc.的首席运营官。加入Trine以前，从1996年到2001年，Noyes先生担任过吉尔泰克斯制药公司（GelTex Pharmaceuticals）的几个管理职位，之后该公司被美国健赞公司（Genzyme Corporation）收购。收购以后，从2001年到2002年，他担任过吉尔泰克斯制药公司的总裁与肾脏部门的总裁。加入吉尔泰克斯制药公司前，他在美国默克公司（Merck & Co.）的高血压和心力衰竭事业部和管理式照护部门的多个职位任职几年，并研究其依那普利和奥美拉唑产品。Noyes先生在哈佛学院（Harvard College）获得文学学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
Timothy P. Noyes has served as our Chief Executive Officer since February 2021 and a member of our board of directors since April 2021. Prior to joining the Company, from October 2019 to February 2021 Mr. Noyes served as President and Chief Executive Officer and a member of the board of directors of Arcuate Therapeutics, Inc. From April 2006 to September 2019 Mr. Noyes served as a member of the board of directors of ArTara Therapeutics, Inc., publicly traded pharmaceutical company formerly known as Proteon Therapeutics, Inc., or Proteon. From April 2006 to January 2020 Mr. Noyes also served as President and Chief Executive Officer of Proteon, until Proteon completed its merger with ArTara Therapeutics Inc. From January 2002 to March 2006 Mr. Noyes served as Chief Operating Officer of Trine Pharmaceuticals, Inc., or Trine. Before joining Trine, Mr. Noyes held several management positions with GelTex Pharmaceuticals Inc. from 1996 to 2001 prior to its acquisition by Genzyme Corporation. After the acquisition, from 2001 to 2002 he held the positions of President, Renal Division and President, GelTex Pharmaceuticals. Prior to GelTex, he worked for several years at Merck & Co. across multiple roles in its hypertension and heart failure group and managed care division, and on its Vasotec and Prilosec products. Mr. Noyes received an A.B. from Harvard College and an M.B.A. from Harvard Business School.- Timothy P. Noyes于2006年4月加入Proteon，担任我司总裁兼首席执行官，还从加入Proteon开始一直担任我司董事。从2002年到2006年，Noyes先生担任Trine Pharmaceuticals, Inc.的首席运营官。加入Trine以前，从1996年到2001年，Noyes先生担任过吉尔泰克斯制药公司（GelTex Pharmaceuticals）的几个管理职位，之后该公司被美国健赞公司（Genzyme Corporation）收购。收购以后，从2001年到2002年，他担任过吉尔泰克斯制药公司的总裁与肾脏部门的总裁。加入吉尔泰克斯制药公司前，他在美国默克公司（Merck & Co.）的高血压和心力衰竭事业部和管理式照护部门的多个职位任职几年，并研究其依那普利和奥美拉唑产品。Noyes先生在哈佛学院（Harvard College）获得文学学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
- Timothy P. Noyes has served as our Chief Executive Officer since February 2021 and a member of our board of directors since April 2021. Prior to joining the Company, from October 2019 to February 2021 Mr. Noyes served as President and Chief Executive Officer and a member of the board of directors of Arcuate Therapeutics, Inc. From April 2006 to September 2019 Mr. Noyes served as a member of the board of directors of ArTara Therapeutics, Inc., publicly traded pharmaceutical company formerly known as Proteon Therapeutics, Inc., or Proteon. From April 2006 to January 2020 Mr. Noyes also served as President and Chief Executive Officer of Proteon, until Proteon completed its merger with ArTara Therapeutics Inc. From January 2002 to March 2006 Mr. Noyes served as Chief Operating Officer of Trine Pharmaceuticals, Inc., or Trine. Before joining Trine, Mr. Noyes held several management positions with GelTex Pharmaceuticals Inc. from 1996 to 2001 prior to its acquisition by Genzyme Corporation. After the acquisition, from 2001 to 2002 he held the positions of President, Renal Division and President, GelTex Pharmaceuticals. Prior to GelTex, he worked for several years at Merck & Co. across multiple roles in its hypertension and heart failure group and managed care division, and on its Vasotec and Prilosec products. Mr. Noyes received an A.B. from Harvard College and an M.B.A. from Harvard Business School.
- George A. Eldridge
George A. Eldridge于2013年9月加入Proteon，担任我司高级副总裁兼首席财务官。加入Proteon前，从2009年到2013年，Eldridge先生担任生物技术行业内公司的顾问，担任首席财务官，并提供顾问服务。从2006年到2009年，Eldridge先生担任Targanta Therapeutics Corporation的首席财务官直到其于2009年被医药公司（The Medicines Company）收购。在Targanta任职前，从2002年到2006年，Eldridge先生担任赛龙生物公司（Therion Biologics）的首席财务官。赛龙生物公司于2006年第四季度根据联邦破产法的规定申请破产保护，但被驳回。加入赛龙生物公司前，Eldridge先生担任Curis, Inc.的首席财务官，在这之前，担任Ontogeny, Inc.与Boston Life Sciences, Inc.的首席财务官。在生物技术领域任职前，Eldridge先生是基德尔·皮博迪公司（Kidder Peabody & Co, Inc.）的投资银行家。他在达特茅斯学院（Dartmouth College）获得文学学士学位，并在芝加哥大学（University of Chicago）布斯商学院获得工商管理硕士学位。
George A. Eldridge has served as our Chief Financial Officer since March 2021. Prior to joining our company, from October 2020 to March 2021 Mr. Eldridge served as Senior Vice President and Chief Financial Officer of Lyndra Therapeutics, Inc., or Lyndra, after consulting with Lyndra since August 2020. Prior to joining Lyndra, from February 2020 to October 2020 Mr. Eldridge served as a consultant and acting Chief Financial Officer to Sollis Therapeutics Inc. From September 2013 to January 2020 Mr. Eldridge was Senior Vice President and Chief Financial Officer of Proteon. Prior to joining Proteon, from 2009 to 2013 Mr. Eldridge served as a consultant to various companies in the biotechnology industry, acting as a chief financial officer and providing advisory services. From September 2006 to March 2009 Mr. Eldridge was Chief Financial Officer of Targanta Therapeutics Corporation until its acquisition in 2009 by The Medicines Company. Before working at Targanta, Mr. Eldridge served as Chief Financial Officer of Therion Biologics Corporation, or Therion, from 2002 to 2006. Prior to Therion, Mr. Eldridge served as Chief Financial Officer of Curis, Inc. previously Ontogeny, Inc. and Boston Life Sciences, Inc. Prior to working in the biotechnology field, Mr. Eldridge was an investment banker at Kidder Peabody & Co, Inc. Mr. Eldridge holds a B.A. from Dartmouth College and an M.B.A. from the University of Chicago, Booth School of Business.- George A. Eldridge于2013年9月加入Proteon，担任我司高级副总裁兼首席财务官。加入Proteon前，从2009年到2013年，Eldridge先生担任生物技术行业内公司的顾问，担任首席财务官，并提供顾问服务。从2006年到2009年，Eldridge先生担任Targanta Therapeutics Corporation的首席财务官直到其于2009年被医药公司（The Medicines Company）收购。在Targanta任职前，从2002年到2006年，Eldridge先生担任赛龙生物公司（Therion Biologics）的首席财务官。赛龙生物公司于2006年第四季度根据联邦破产法的规定申请破产保护，但被驳回。加入赛龙生物公司前，Eldridge先生担任Curis, Inc.的首席财务官，在这之前，担任Ontogeny, Inc.与Boston Life Sciences, Inc.的首席财务官。在生物技术领域任职前，Eldridge先生是基德尔·皮博迪公司（Kidder Peabody & Co, Inc.）的投资银行家。他在达特茅斯学院（Dartmouth College）获得文学学士学位，并在芝加哥大学（University of Chicago）布斯商学院获得工商管理硕士学位。
- George A. Eldridge has served as our Chief Financial Officer since March 2021. Prior to joining our company, from October 2020 to March 2021 Mr. Eldridge served as Senior Vice President and Chief Financial Officer of Lyndra Therapeutics, Inc., or Lyndra, after consulting with Lyndra since August 2020. Prior to joining Lyndra, from February 2020 to October 2020 Mr. Eldridge served as a consultant and acting Chief Financial Officer to Sollis Therapeutics Inc. From September 2013 to January 2020 Mr. Eldridge was Senior Vice President and Chief Financial Officer of Proteon. Prior to joining Proteon, from 2009 to 2013 Mr. Eldridge served as a consultant to various companies in the biotechnology industry, acting as a chief financial officer and providing advisory services. From September 2006 to March 2009 Mr. Eldridge was Chief Financial Officer of Targanta Therapeutics Corporation until its acquisition in 2009 by The Medicines Company. Before working at Targanta, Mr. Eldridge served as Chief Financial Officer of Therion Biologics Corporation, or Therion, from 2002 to 2006. Prior to Therion, Mr. Eldridge served as Chief Financial Officer of Curis, Inc. previously Ontogeny, Inc. and Boston Life Sciences, Inc. Prior to working in the biotechnology field, Mr. Eldridge was an investment banker at Kidder Peabody & Co, Inc. Mr. Eldridge holds a B.A. from Dartmouth College and an M.B.A. from the University of Chicago, Booth School of Business.
- Benjamin T. Dake
Benjamin T.Dake创立了公司，自2018年7月起担任总裁，自2020年9月起担任首席运营官，自2020年8月起担任秘书。他于2018年7月至2021年2月担任我们的首席执行官，并于2018年7月至2021年4月担任我们的董事会成员。在加入我们公司之前，Dake博士于2015年9月至2019年12月在投资公司RA Capital Management，L.P.担任多个职位，包括风险合伙人和风险分析师。从2007年到2010年，Dake博士在神经退行性疾病中心的Brigham and Women’；s医院进行了具有二级技术研究助理头衔的研究。在从事科学工作之前，1992年至2004年，Dake博士受雇于盖洛普组织（Gallup Organization），在那里他担任过各种与信息技术相关的职务，并且是他们的互联网数据收集企业的创始人，Dake博士获得了内布拉斯加林肯大学的学士和硕士学位，并获得了细胞博士学位，塔夫茨大学医学院的分子和发展生物学。
Benjamin T. Dake founded the Company and has served as our President since July 2018 our Chief Operating Officer since September 2020 and our Secretary since August 2020. He served as our Chief Executive Officer from July 2018 until February 2021 and served as a member of our board of directors from July 2018 to April 2021. Prior to joining our company, Dr. Dake served in a number of positions of ascending responsibility at the investment firm RA Capital Management, L.P. from September 2015 until December 2019 including as a Venture Associate and Venture Analyst. From 2007 to 2010 Dr. Dake conducted research holding the title of Technical Research Assistant II at Brigham and Women’s Hospital at the Center for Neurodegenerative Disease. Before working in science, Dr. Dake was employed by the Gallup Organization from 1992 to 2004 where he held various information technology related positions and was a founder of their internet data collection venture “g.” Dr. Dake received a B.S. and an M.S. from University of Nebraska-Lincoln and a Ph.D. in cell, molecular and development biology from Tufts University School of Medicine.- Benjamin T.Dake创立了公司，自2018年7月起担任总裁，自2020年9月起担任首席运营官，自2020年8月起担任秘书。他于2018年7月至2021年2月担任我们的首席执行官，并于2018年7月至2021年4月担任我们的董事会成员。在加入我们公司之前，Dake博士于2015年9月至2019年12月在投资公司RA Capital Management，L.P.担任多个职位，包括风险合伙人和风险分析师。从2007年到2010年，Dake博士在神经退行性疾病中心的Brigham and Women’；s医院进行了具有二级技术研究助理头衔的研究。在从事科学工作之前，1992年至2004年，Dake博士受雇于盖洛普组织（Gallup Organization），在那里他担任过各种与信息技术相关的职务，并且是他们的互联网数据收集企业的创始人，Dake博士获得了内布拉斯加林肯大学的学士和硕士学位，并获得了细胞博士学位，塔夫茨大学医学院的分子和发展生物学。
- Benjamin T. Dake founded the Company and has served as our President since July 2018 our Chief Operating Officer since September 2020 and our Secretary since August 2020. He served as our Chief Executive Officer from July 2018 until February 2021 and served as a member of our board of directors from July 2018 to April 2021. Prior to joining our company, Dr. Dake served in a number of positions of ascending responsibility at the investment firm RA Capital Management, L.P. from September 2015 until December 2019 including as a Venture Associate and Venture Analyst. From 2007 to 2010 Dr. Dake conducted research holding the title of Technical Research Assistant II at Brigham and Women’s Hospital at the Center for Neurodegenerative Disease. Before working in science, Dr. Dake was employed by the Gallup Organization from 1992 to 2004 where he held various information technology related positions and was a founder of their internet data collection venture “g.” Dr. Dake received a B.S. and an M.S. from University of Nebraska-Lincoln and a Ph.D. in cell, molecular and development biology from Tufts University School of Medicine.
- Hunter Gillies
Hunter Gillies自2020年5月起担任我们的首席医疗官，并于2019年6月至2020年4月担任公司顾问。吉利斯博士在开发治疗肺血管疾病的药物方面有20多年的经验。加入公司之前，从2015年到2020年4月，Gillies博士在肺动脉高压领域工作的多家生物技术和生物制药公司（PAH，Actelion Pharmaceuticals Ltd.，PhaseBioPharmaceuticals，Inc.和Altavant Sciences，Inc.）担任顾问，以及心力衰竭领域的公司，包括Cardurion Pharmaceuticals，Inc.。2010年2月至2015年12月，Gillies博士是Gilead Sciences的临床研究高级总监，在那里他负责领导肺血管疾病团队，并领导了针对PAH患者的临床试验Ambition Study的美国部分。在加入Gilead之前，Gillies博士从1998年到2010年在辉瑞公司担任过许多职责不断增加的职位，在那里他负责关于性健康，心血管疾病和肺血管疾病的临床研究试验，包括监督Revatio计划，这是一种批准用于PAH的药物。Gillies博士获得了工商管理硕士学位。和B.SC.拥有南非开普敦大学的运动生理学博士学位，以及伦敦玛丽皇后大学的运动医学文凭。
Hunter Gillies has served as our Chief Medical Officer since May 2020 and was a consultant for the Company from June 2019 to April 2020. Dr. Gillies has more than 20 years’ experience in developing drugs to treat pulmonary vascular disease. Prior to joining the Company, Dr. Gillies consulted from 2015 to April 2020 with a number of biotechnology and biopharmaceutical companies working in the field of pulmonary arterial hypertension, or PAH, Actelion Pharmaceuticals Ltd., PhaseBio Pharmaceuticals, Inc., and Altavant Sciences, Inc., as well as with companies in the field of heart failure, including Cardurion Pharmaceuticals, Inc. From February 2010 to December 2015 Dr. Gillies was a Senior Director in clinical research at Gilead Sciences where he was responsible for leading the pulmonary vascular disease team and led the U.S. component of the AMBITION study, a clinical trial for patients suffering from PAH. Prior to Gilead, Dr. Gillies held a number of positions of increasing responsibility at Pfizer from 1998 until 2010 where he was responsible for clinical research trials in sexual health, cardiovascular disease, and pulmonary vascular disease, including overseeing the Revatio program, a drug approved for PAH. Dr. Gillies earned his M.B.Ch.B., M.Sc. and B.Sc. in Exercise Physiology from the University of Cape Town, South Africa, and his diploma in Sports Medicine from Queen Mary University in London.- Hunter Gillies自2020年5月起担任我们的首席医疗官，并于2019年6月至2020年4月担任公司顾问。吉利斯博士在开发治疗肺血管疾病的药物方面有20多年的经验。加入公司之前，从2015年到2020年4月，Gillies博士在肺动脉高压领域工作的多家生物技术和生物制药公司（PAH，Actelion Pharmaceuticals Ltd.，PhaseBioPharmaceuticals，Inc.和Altavant Sciences，Inc.）担任顾问，以及心力衰竭领域的公司，包括Cardurion Pharmaceuticals，Inc.。2010年2月至2015年12月，Gillies博士是Gilead Sciences的临床研究高级总监，在那里他负责领导肺血管疾病团队，并领导了针对PAH患者的临床试验Ambition Study的美国部分。在加入Gilead之前，Gillies博士从1998年到2010年在辉瑞公司担任过许多职责不断增加的职位，在那里他负责关于性健康，心血管疾病和肺血管疾病的临床研究试验，包括监督Revatio计划，这是一种批准用于PAH的药物。Gillies博士获得了工商管理硕士学位。和B.SC.拥有南非开普敦大学的运动生理学博士学位，以及伦敦玛丽皇后大学的运动医学文凭。
- Hunter Gillies has served as our Chief Medical Officer since May 2020 and was a consultant for the Company from June 2019 to April 2020. Dr. Gillies has more than 20 years’ experience in developing drugs to treat pulmonary vascular disease. Prior to joining the Company, Dr. Gillies consulted from 2015 to April 2020 with a number of biotechnology and biopharmaceutical companies working in the field of pulmonary arterial hypertension, or PAH, Actelion Pharmaceuticals Ltd., PhaseBio Pharmaceuticals, Inc., and Altavant Sciences, Inc., as well as with companies in the field of heart failure, including Cardurion Pharmaceuticals, Inc. From February 2010 to December 2015 Dr. Gillies was a Senior Director in clinical research at Gilead Sciences where he was responsible for leading the pulmonary vascular disease team and led the U.S. component of the AMBITION study, a clinical trial for patients suffering from PAH. Prior to Gilead, Dr. Gillies held a number of positions of increasing responsibility at Pfizer from 1998 until 2010 where he was responsible for clinical research trials in sexual health, cardiovascular disease, and pulmonary vascular disease, including overseeing the Revatio program, a drug approved for PAH. Dr. Gillies earned his M.B.Ch.B., M.Sc. and B.Sc. in Exercise Physiology from the University of Cape Town, South Africa, and his diploma in Sports Medicine from Queen Mary University in London.
- Ralph Niven
拉尔夫·尼文（Ralph Niven）自2020年7月起担任我们的首席发展官，并于2018年5月至2020年4月担任公司顾问。自2017年3月以来，Niven博士还一直担任斯坦福大学Spark转化医学计划的科学与发展顾问。2012年8月至2017年1月，Niven博士在诺华制药公司或生物制药公司诺华担任首席研究员，并负责几个早期吸入计划的技术开发。在加入诺华之前，Niven博士于2007年9月至2012年1月担任APT Pharmaceuticals，Inc.或APT的首席技术官，在此期间，APT完成了用于肺移植慢性排斥反应的环孢素吸入制剂的III期研究。加入APT之前，2001年至2005年，他曾担任WindtreeTherapeutics，Inc.（前身为Discovery Laboratories，Inc.）的临床前开发高级副总裁，在那里他建立并管理公司’；S California研发设施，专注于合成肺表面活性剂的气溶胶应用。Niven博士还曾在Megabios Corp.（一家专注于细胞和基因治疗的公司）、Advanced Inhalation Research，Inc.（一家生物制药公司，后被Alkermes，Inc.收购）任职，在那里Niven博士促进了干粉“；多孔”；颗粒的开发，Amgen，Inc.（一家制药公司），作为一名研究科学家，正在开发通过肺部输送的生物分子。Niven博士拥有肯塔基大学（University of Kentucky）的药学博士学位，斯特拉斯克莱德大学（University of Strathclyde）的药学学士学位，并拥有乔治华盛顿大学（George Washington University）的医疗保健工商管理硕士学位。
Ralph Niven has served as our Chief Development Officer since July 2020 and was a consultant for the Company from May 2018 to April 2020. Since March 2017 Dr. Niven has also served as scientific and development advisor to the SPARK translational medicine program at Stanford University. From August 2012 to January 2017 Dr. Niven held the position of Principal Fellow at Novartis Pharmaceuticals Corporation, or Novartis, a biopharmaceutical company, and was responsible for the technical development of several early-stage inhalation programs. Prior to Novartis, Dr. Niven served as Chief Technology Officer from September 2007 to January 2012 for APT Pharmaceuticals, Inc., or APT, during which time APT completed a Phase III study of an inhaled formulation of cyclosporine for chronic rejection in lung transplantation. Prior to APT, Dr. Niven served as Senior Vice President of Preclinical Development for Windtree Therapeutics, Inc., formerly known as Discovery Laboratories, Inc. from 2001 to 2005 where he established and ran the company’s California R&D facility focusing on aerosol applications of a synthetic lung surfactant. Dr. Niven also held positions at Megabios Corp., a company focused on cell and gene therapy, Advanced Inhalation Research, Inc., a biopharmaceutical company subsequently acquired by Alkermes, Inc., where Dr. Niven facilitated the development of dry powder “porous” particles for inhalation, Amgen, Inc., a pharmaceutical company, as a research scientist developing biomolecules for delivery via the lungs. Dr. Niven holds a Ph.D. in Pharmaceutical Sciences from the University of Kentucky and has an undergraduate degree in Pharmacy from the University of Strathclyde and holds an M.B.A. in Healthcare from George Washington University.- 拉尔夫·尼文（Ralph Niven）自2020年7月起担任我们的首席发展官，并于2018年5月至2020年4月担任公司顾问。自2017年3月以来，Niven博士还一直担任斯坦福大学Spark转化医学计划的科学与发展顾问。2012年8月至2017年1月，Niven博士在诺华制药公司或生物制药公司诺华担任首席研究员，并负责几个早期吸入计划的技术开发。在加入诺华之前，Niven博士于2007年9月至2012年1月担任APT Pharmaceuticals，Inc.或APT的首席技术官，在此期间，APT完成了用于肺移植慢性排斥反应的环孢素吸入制剂的III期研究。加入APT之前，2001年至2005年，他曾担任WindtreeTherapeutics，Inc.（前身为Discovery Laboratories，Inc.）的临床前开发高级副总裁，在那里他建立并管理公司’；S California研发设施，专注于合成肺表面活性剂的气溶胶应用。Niven博士还曾在Megabios Corp.（一家专注于细胞和基因治疗的公司）、Advanced Inhalation Research，Inc.（一家生物制药公司，后被Alkermes，Inc.收购）任职，在那里Niven博士促进了干粉“；多孔”；颗粒的开发，Amgen，Inc.（一家制药公司），作为一名研究科学家，正在开发通过肺部输送的生物分子。Niven博士拥有肯塔基大学（University of Kentucky）的药学博士学位，斯特拉斯克莱德大学（University of Strathclyde）的药学学士学位，并拥有乔治华盛顿大学（George Washington University）的医疗保健工商管理硕士学位。
- Ralph Niven has served as our Chief Development Officer since July 2020 and was a consultant for the Company from May 2018 to April 2020. Since March 2017 Dr. Niven has also served as scientific and development advisor to the SPARK translational medicine program at Stanford University. From August 2012 to January 2017 Dr. Niven held the position of Principal Fellow at Novartis Pharmaceuticals Corporation, or Novartis, a biopharmaceutical company, and was responsible for the technical development of several early-stage inhalation programs. Prior to Novartis, Dr. Niven served as Chief Technology Officer from September 2007 to January 2012 for APT Pharmaceuticals, Inc., or APT, during which time APT completed a Phase III study of an inhaled formulation of cyclosporine for chronic rejection in lung transplantation. Prior to APT, Dr. Niven served as Senior Vice President of Preclinical Development for Windtree Therapeutics, Inc., formerly known as Discovery Laboratories, Inc. from 2001 to 2005 where he established and ran the company’s California R&D facility focusing on aerosol applications of a synthetic lung surfactant. Dr. Niven also held positions at Megabios Corp., a company focused on cell and gene therapy, Advanced Inhalation Research, Inc., a biopharmaceutical company subsequently acquired by Alkermes, Inc., where Dr. Niven facilitated the development of dry powder “porous” particles for inhalation, Amgen, Inc., a pharmaceutical company, as a research scientist developing biomolecules for delivery via the lungs. Dr. Niven holds a Ph.D. in Pharmaceutical Sciences from the University of Kentucky and has an undergraduate degree in Pharmacy from the University of Strathclyde and holds an M.B.A. in Healthcare from George Washington University.